| Literature DB >> 31194188 |
Brandi N Snyder-Talkington1, Chunlin Dong1, Vincent Castranova2, Yong Qian3, Nancy L Guo1,4.
Abstract
Concurrent with rising production of carbon-based engineered nanomaterials is a potential increase in respiratory and cardiovascular diseases due to exposure to nanomaterials in the workplace atmosphere. While single-cell models of pulmonary exposure are often used to determine the potential toxicity of nanomaterials in vitro, previous studies have shown that coculture cell models better represent the cellular response and crosstalk that occurs in vivo. This study identified differential gene regulation in human small airway epithelial cells (SAECs) grown either in monoculture or in coculture with human microvascular endothelial cells following exposure of the SAECs to multiwalled carbon nanotubes (MWCNTs). SAEC genes that either changed their regulation direction from upregulated in monoculture to downregulated in coculture (or vice versa) or had a more than a two-fold changed in the same regulation direction were identified. Genes that changed regulation direction were most often involved in the processes of cellular growth and proliferation and cellular immune response and inflammation. Genes that had a more than a two-fold change in regulation in the same direction were most often involved in the inflammatory response. The direction and fold-change of this differential gene regulation suggests that toxicity testing in monoculture may exaggerate cellular responses to MWCNTs, and coculture of cells may provide a more in-depth assessment of toxicological responses.Entities:
Keywords: Coculture; Gene regulation; MWCNT; Multiwalled carbon nanotubes; Pulmonary exposure
Year: 2019 PMID: 31194188 PMCID: PMC6554470 DOI: 10.1016/j.toxrep.2019.05.010
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Top 10 “changed regulation direction” SAEC genes with the biggest difference in fold change between monoculture and coculture.
| Gene Name | Fold Change in Monoculture | Fold Change in Coculture | Function |
|---|---|---|---|
| ACBD3 | 3.53 (24 h) | −3.77 (24 h) | Maintenance of Golgi structure and function; hormonal regulation of steroid formation |
| DMRTA1 | 3.32 (6 h) | −4.15 (6 h) | Unknown |
| EXOC6B | 2.56 (6 h) | −4.85 (6 h) | Exocytosis |
| FAM198B | 6.63 (6 h) | −2.45 (6 h) | Unknown |
| GHR | 3.30 (24 h) | −3.69 (24 h) | Growth |
| IL1R1 | 2.83 (24 h) | −2.91 (24 h) | Cytokine-induced immune and inflammatory responses |
| IRF2 | 2.31 (24 h) | −3.57 (24 h) | Inhibits interferon alpha and beta transcription |
| LONRF1 | 2.19 (6 h) | −4.43 (6 h) | Immune response |
| PARM1 | 2.83 (24 h) | −5.89 (24 h) | Apoptosis resistance |
| ZNF304 | 2.21 (24 h) | −3.15 (24 h) | Transcriptional repressor |
Fig. 1Top 10 IPA pathways involving SAEC genes that changed regulation direction.
Fig. 2IPA disease and function overlays for SAEC genes that changed regulation direction.
Fold changes of SAEC genes that changed regulation direction between monoculture and coculture identified in IPA overlays.
| Gene Name | Fold Change in Monoculture | Fold Change in Coculture |
|---|---|---|
| ACBD3* | 3.53 (24 h) | −3.77 (24 h) |
| CD9* | 2.47 (6 h) | −1.91 (6 h) |
| CFTR* | 2.74 (6 h) | −3.90 (6 h) |
| FGFR2* | 2.60 (6 h) | −2.89 (6 h) |
| GJA1* | 2.54 (6 h) | −2.94 (6 h) |
| IL1R1* | 2.83 (24 h) | −2.91 (24 h) |
| IRF2 | 2.31 (24 h) | −3.57 (24 h) |
| SMAD9* | 2.54 (6 h) | −2.12 (6 h) |
| SNAI1* | 4.58 (6 h) | −2.51 (6 h) |
| TET2 | 2.19 (24 h) | −2.79 (24 h) |
| TNFSF4* | 2.73 (24 h) | −2.74 (24 h) |
| VEGFA* | −2.00 (6 h) | 2.08 (6 h) |
Top 10 “same regulation direction” SAEC genes with the biggest difference in fold change between monoculture and coculture.
| Gene Name | Fold Change in Monoculture | Fold Change in Coculture | Fold Change Difference | Function |
|---|---|---|---|---|
| CXCL1 | −125.33 (6 h) | −3.43 (6 h) | 121.90 | Inflammation; chemoattractant for neutrophils |
| DAPL1 | 56.67 (6 h) | 10.71 (6 h) | 45.97 | Epithelial differentiation; apoptosis |
| MMP3 | −45.36 (6 h) | −2.83 (6 h) | 42.53 | Wound repair; progression of atherosclerosis; tumor initiation |
| CXCL2 | −40.14 (6 h) | −3.04 (6 h) | 37.10 | Inflammation and suppression of hematopoietic progenitor cell proliferation |
| TOP2A | −3.06 (6 h) | −28.63 (6 h) | 25.57 | DNA regulation during transcription |
| DMTB1 | −33.79 (6 h) | −13.76 (6 h) | 20.03 | Interaction of tumor cells and the immune system |
| SAA4 | −18.58 (6 h) | −2.08 (6 h) | 16.50 | Acute phase reactant; inflammation |
| STEAP4 | −17.23 (6 h) | −3.68 (6 h) | 13.55 | Inflammation |
| PTX3 | −14.72 (6 h) | −2.53 (6 h) | 12.19 | Inflammation regulation; complement activation |
| SPON2 | 12.47 (6 h) | 2.91 (6 h) | 9.56 | Cell adhesion |
Fig. 3Top 10 IPA pathways involving SAEC genes that had a more than 2-fold difference in the same regulation direction.
Fig. 4IPA disease and function overlays for SAEC genes that had a more than two-fold difference in the same regulation direction.
Fold changes of SAEC genes that had a more than 2-fold difference in the same regulation direction between monoculture and coculture identified in IPA overlays.
| Gene Name | Fold Change in Monoculture | Fold Change in Coculture | Fold Change Difference |
|---|---|---|---|
| CDKN1A | −4.98 (6 h) | −2.45 (6 h) | 2.53 |
| CXCL1 | −125.33 (6 h) | −3.43 (6 h) | 121.91 |
| CXCL2 | −40.14 (6 h) | −3.04 (6 h) | 37.10 |
| CXCL3 | −15.82 (6 h) | −6.71 (6 h) | 9.11 |
| IL1R1 | −2.82 (6 h) | −5.35 (6 h) | 2.53 |
| PDE4B | −7.77 (6 h) | −5.00 (6 h) | 2.77 |
| PTX3 | −14.72 (6 h) | −2.53 (6 h) | 12.19 |
| SERPINE1 | −2.98 (6 h) | −5.04 (6 h) | 2.06 |
| SLC39A8 | −11.80 (6 h) | −3.16 (6 h) | 8.64 |
| SMURF2 | 7.45 (24 h) | 3.43 (24 h) | 4.02 |
| TLR2 | −5.56 (6 h) | −3.10 (6 h) | 2.46 |
| TTK | −2.23 (6 h) | −5.76 (6 h) | 3.51 |